IKT vs. TYRA, MAZE, VALN, SEPN, ATYR, MREO, CGEM, AMLX, ZYBT, and ORKA
Should you be buying Inhibikase Therapeutics stock or one of its competitors? The main competitors of Inhibikase Therapeutics include Tyra Biosciences (TYRA), Maze Therapeutics (MAZE), Valneva (VALN), Septerna (SEPN), aTyr Pharma (ATYR), Mereo BioPharma Group (MREO), Cullinan Therapeutics (CGEM), Amylyx Pharmaceuticals (AMLX), Zhengye Biotechnology (ZYBT), and Oruka Therapeutics (ORKA). These companies are all part of the "pharmaceutical products" industry.
Inhibikase Therapeutics vs. Its Competitors
Tyra Biosciences (NASDAQ:TYRA) and Inhibikase Therapeutics (NYSE:IKT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.
Tyra Biosciences is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks.
Tyra Biosciences' return on equity of -26.90% beat Inhibikase Therapeutics' return on equity.
Tyra Biosciences has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500. Comparatively, Inhibikase Therapeutics has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500.
84.1% of Tyra Biosciences shares are owned by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 15.2% of Tyra Biosciences shares are owned by insiders. Comparatively, 7.3% of Inhibikase Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, Tyra Biosciences had 2 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 6 mentions for Tyra Biosciences and 4 mentions for Inhibikase Therapeutics. Inhibikase Therapeutics' average media sentiment score of 0.40 beat Tyra Biosciences' score of -0.08 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media.
Tyra Biosciences currently has a consensus price target of $30.83, indicating a potential upside of 208.49%. Inhibikase Therapeutics has a consensus price target of $6.50, indicating a potential upside of 243.92%. Given Inhibikase Therapeutics' higher probable upside, analysts clearly believe Inhibikase Therapeutics is more favorable than Tyra Biosciences.
Summary
Tyra Biosciences beats Inhibikase Therapeutics on 9 of the 13 factors compared between the two stocks.
Get Inhibikase Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for IKT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding IKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Inhibikase Therapeutics Competitors List
Related Companies and Tools
This page (NYSE:IKT) was last updated on 7/4/2025 by MarketBeat.com Staff
